French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

To be part of this study, you would need to be a patient in France who has a blood cancer for which CAR-T cell therapy is a possible treatment. This includes people who have already received CAR-T cell therapy since July 2018, or those who are about to receive it now. The decision for CAR-T treatment must have been made by a team of specialist doctors during a meeting called a 'multidisciplinary tumour board' (RCP).

It's also important that if you are alive, you either give your permission, or you don't object to your health information being collected and used for this study. If a patient is no longer with us, their past wishes about data use would be respected. This study focuses specifically on patients who have access to the French healthcare system and are registered for social security in France.

This study is a registry, so what you're doing is allowing your medical information to be collected. There are no extra hospital visits, assessments, or medications you'd need to take specifically for this study. The information collected comes from your standard medical care.

For patients who have already had CAR-T cell treatment since July 2018, their past medical records will be used. For those who are newly considered for CAR-T cell treatment, your medical information will be collected as you go through the process of diagnosis, treatment, and follow-up. The study just gathers data from your regular medical journey, rather than asking you to do anything extra. This means there's no set total duration for your participation; it just involves collecting your existing medical care details.